Abstract 707P
Background
Although oral targeted therapies used in oncology demonstrate high interpatient variability in pharmacokinetics (PK), resulting in overdosing (>15%) and underdosing (30%) of patients (pts), a standard fixed dose for all pts is still used. This could lead to unnecessary toxicity and decreased efficacy, considering the established exposure–response and –toxicity relationships for many of these drugs. Personalised dosing through therapeutic drug monitoring (TDM) – individual dose adjustments based on measured PK–levels – could improve treatment outcomes. Results of 600 pts were published last year (Groenland et al, Ann Oncol. 1071-82, 2022 Oct). We hereby provide results of additional enrolment up to a 1000 pts, longer follow–up and newly reviewed cohorts.
Methods
This ongoing prospective study focusses on the feasibility, efficacy and tolerability of TDM of multiple oral targeted therapies in oncology. PK–levels are measured at 4–8–12 weeks after start of treatment and every 12 weeks thereafter. Recommendations are given based on established efficacy targets. Recommended interventions include dose adjustments, intake with food, split of intake moments, emphasize compliance and adjustment of interacting medication. An intervention is considered successful if there is a PK–level above target after intervention and if there is no dose limiting toxicity observed within one month.
Results
As of May 1st 2023, this study includes 1006 pts from 14 hospitals using one of 24 different oral targeted therapies. The largest cohorts are abiraterone (n = 189), imatinib (n = 165), sunitinib (n = 112) and pazopanib (n = 106). Among 916 evaluable pts, 41.3% (n = 378) had all PK–levels above target, while 58.7% (n = 538) had ≥1 PK–level below target. A PK-guided intervention was possible in 55.4% (n = 298), and was successful in 69.1% of cases. Of all pts with a PK-level below target, intervention was successful in 38.3%. As a result, there was a 22.5% gain in pts with PK-levels above target, reaching a total of 63.8% (n = 584).
Conclusions
The results of this study support the feasibility of TDM of oral targeted therapies in oncology. Before implementation, efficacy of TDM still requires further evaluation. For the largest cohorts this evaluation will be performed.
Clinical trial identification
Netherlands Trial Register NTR6866, Release date: 6 December 2017.
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute-Antoni van Leeuwenhoek.
Funding
Unrestricted Research Grants from Ipsen, GSK, Merck, Novartis, Pfizer, Roche.
Disclosure
P. Hamberg: Financial Interests, Personal, Advisory Board: Astellas, MSD, Pfizer, AstraZeneca, BMS, Ipsen. H. Gelderblom: Financial Interests, Institutional, Invited Speaker: Daiichi Sankyo, Deciphera, Novartis, Boehringer Ingelheim, AmMax Bio, Debiopharm, Cytovation. A.K.L. Reyners: Financial Interests, Institutional, Other, Member of the board: Dutch Society of Medical Oncology; Financial Interests, Institutional, Invited Speaker, FIRST study; coordinator for the Netherlands: Tesaro; Financial Interests, Institutional, Invited Speaker, Local PI GCT1015-05 study: Genmab; Financial Interests, Institutional, Invited Speaker, Local PI for the RUBY study: Tesaro; Financial Interests, Institutional, Invited Speaker, Local PI of the R2810 study: Regeneron; Financial Interests, Institutional, Invited Speaker, PI of MK3475-C93 trial: Merck; Non-Financial Interests, Leadership Role, Chairperson of the group that advises the Dutch Society of Medical Oncology whether EMA authorised medication should be common practice in the Netherlands (cieBOM): Dutch Society of Medical Oncology. N.P. Van Erp: Financial Interests, Institutional, Invited Speaker: Wad 'n Workshop; Financial Interests, Institutional, Invited Speaker, IDS: Ipsen, Astellas. R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis; Financial Interests, Institutional, Invited Speaker: Pamgene. N. Steeghs: Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Luszana; Financial Interests, Institutional, Invited Speaker: AbbVie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Crescendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GSK, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer, Deciphera, GSK, Merck, Novartis, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17